1. Home
  2. ELVN vs ELME Comparison

ELVN vs ELME Comparison

Compare ELVN & ELME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ELVN
  • ELME
  • Stock Information
  • Founded
  • ELVN 2016
  • ELME 1960
  • Country
  • ELVN United States
  • ELME United States
  • Employees
  • ELVN N/A
  • ELME N/A
  • Industry
  • ELVN Biotechnology: Pharmaceutical Preparations
  • ELME Real Estate Investment Trusts
  • Sector
  • ELVN Health Care
  • ELME Real Estate
  • Exchange
  • ELVN Nasdaq
  • ELME Nasdaq
  • Market Cap
  • ELVN 1.3B
  • ELME 1.5B
  • IPO Year
  • ELVN 2020
  • ELME N/A
  • Fundamental
  • Price
  • ELVN $25.91
  • ELME $15.96
  • Analyst Decision
  • ELVN Strong Buy
  • ELME Hold
  • Analyst Count
  • ELVN 4
  • ELME 5
  • Target Price
  • ELVN $36.75
  • ELME $17.50
  • AVG Volume (30 Days)
  • ELVN 244.8K
  • ELME 558.3K
  • Earning Date
  • ELVN 11-13-2024
  • ELME 11-04-2024
  • Dividend Yield
  • ELVN N/A
  • ELME 4.53%
  • EPS Growth
  • ELVN N/A
  • ELME N/A
  • EPS
  • ELVN N/A
  • ELME N/A
  • Revenue
  • ELVN N/A
  • ELME $239,523,000.00
  • Revenue This Year
  • ELVN N/A
  • ELME N/A
  • Revenue Next Year
  • ELVN N/A
  • ELME $2.78
  • P/E Ratio
  • ELVN N/A
  • ELME N/A
  • Revenue Growth
  • ELVN N/A
  • ELME 6.62
  • 52 Week Low
  • ELVN $9.80
  • ELME $12.74
  • 52 Week High
  • ELVN $30.03
  • ELME $18.49
  • Technical
  • Relative Strength Index (RSI)
  • ELVN 41.12
  • ELME 33.80
  • Support Level
  • ELVN $24.69
  • ELME $15.56
  • Resistance Level
  • ELVN $26.48
  • ELME $17.89
  • Average True Range (ATR)
  • ELVN 1.38
  • ELME 0.43
  • MACD
  • ELVN -0.32
  • ELME -0.14
  • Stochastic Oscillator
  • ELVN 28.35
  • ELME 13.09

About ELVN Enliven Therapeutics Inc.

Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.

About ELME Elme Communities

Elme Communities is a real estate investment trust engaged in owning and operating properties in the greater Washington DC metropolitan area. The company's real estate portfolio is comprised of office, retail, and multifamily properties located primarily near major transportation nodes. Washington REIT derives nearly all of its income in the form of rental revenue from tenants organized into long-term leases. The company's office assets contribute the majority of this income, while the rest is split fairly evenly between its retail and multifamily locations. Washington REIT's largest tenants are banking, consulting, law, and financial services firms.

Share on Social Networks: